Rejection After ABO-Incompatible Organ Transplantation

  • Ming Cai


Antigen variety, especially HLA discrepancies between the recipients and donors, can cause rejection reaction, which is a complex and hazardous immunological reaction involving multiple cell- and antibody-mediated processes. Similarly for ABOi transplants, previous studies have confirmed that minimization of HLA mismatch is a key to the success of solid organ transplant (Holgersson et al., Transplantation 84:S48–S50, 2007). Allograft rejections are similar to other immunological responses except they are mainly mediated by alloreactive T cells that specifically recognize alloantigen and exert their destructive functions through direct cytotoxicity, NK cell-mediated cytotoxicity, ADCC, complement activation, a variety of pro-inflammatory cytokines, etc. (Holgersson et al., Transplantation 84:S48–S50, 2007 and Subramanian et al., Int J Immunogenet 39:282–290, 2012).

Due to the different underlying mechanisms, rejection reactions can be classified as described in the following chapters and vary on their clinical manifestations as well as managements.


HLA Rejection NK cell Management 


  1. 1.
    Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation. 2003;76:730–1.CrossRefGoogle Scholar
  2. 2.
    Tobian AA, Shirey RS, Montgomery RA, et al. ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant. 2010;10:1247–53.CrossRefGoogle Scholar
  3. 3.
    Montgomery RA, Hardy MA, Jordan SC, et al. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation. 2004;78:181–5.CrossRefGoogle Scholar
  4. 4.
    Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando). 2009;23:34–46.CrossRefGoogle Scholar
  5. 5.
    Madan AK, Slakey DP, Becker A, et al. Treatment of antibody-mediated accelerated rejection using plasmapheresis. J Clin Apher. 2000;15:180–3.CrossRefGoogle Scholar
  6. 6.
    Schwaiger E, Regele H, Wahrmann M, et al. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report. Clin Transpl. 2010:391–6.Google Scholar
  7. 7.
    Peerschke EI, Jesty J, Reid KB, et al. The soluble recombinant form of a binding protein/receptor for the globular domain of c1q(gc1qr) enhances blood coagulation. Blood Coagul Fibrinolysis. 1998;9:29–37.CrossRefGoogle Scholar
  8. 8.
    Brown KK, Henson PM, Maclouf J, et al. Neutrophil-platelet adhesion: relative roles of platelet P-selectin and neutrophil beta2(dc18) integrins. Am J Respir Cell Mol Biol. 1998;18:100–10.CrossRefGoogle Scholar
  9. 9.
    Lin CC, Cooper DK, Dorling A. Coagulation dysregulation as a barrier to xenotransplantation in the primate. Transpl Immunol. 2009;21:75–80.CrossRefGoogle Scholar
  10. 10.
    Lin CC, Ezzelarab M, Shapiro R, et al. Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation. Am J Transplant. 2010;10:1556–68.CrossRefGoogle Scholar
  11. 11.
    Schulte am Esch J II, Cruz MA, Siegel JB, et al. Activation of human platelets by the membrane-expressed A1 domain of von Willebrand factor. Blood. 1997;90:4425–37.PubMedGoogle Scholar
  12. 12.
    Cantu E, Balsara KR, Li B, et al. Prolonged function of macrophage, von Willebrand factor-deficient porcine pulmonary xenografts. Am J Transplant. 2007;7:66–75.CrossRefGoogle Scholar
  13. 13.
    Panes O, Matus V, Saez CG, et al. Human platelets synthesize and express functional tissue factor. Blood. 2007;109:5242–50.CrossRefGoogle Scholar
  14. 14.
    Holgersson J. Can ABO-incompatible organ transplantation pave the way for clinical xenotransplantation? Transplantation. 2007;84:S48–50.CrossRefGoogle Scholar
  15. 15.
    Subramanian V, Ramachandran S, Klein C, et al. ABO-incompatible organ transplantation. Int J Immunogenet. 2012;39:282–90.CrossRefGoogle Scholar
  16. 16.
    Zhang Q, Liang LW, Gjertson DW, et al. Development of posttransplant anti-donor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation. 2005;79:591–8.CrossRefGoogle Scholar
  17. 17.
    Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria—an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant. 2003;3:708–14.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Ming Cai
    • 1
  1. 1.Department of Urology PLA No. 309 HospitalBeijingChina

Personalised recommendations